What is the role of percutaneous transcatheter aortic-valve replacement (TAVR) in the treatment of aortic stenosis (AS)?

Updated: May 07, 2019
  • Author: Xiushui (Mike) Ren, MD; Chief Editor: Terrence X O'Brien, MD, MS, FACC  more...
  • Print
Answer

Many patients with severe aortic stenosis and coexisting conditions are not candidates for, or are at high risk for complications with, surgical replacement of the aortic valve. Studies have suggested that percutaneous transcatheter aortic-valve replacement (TAVR) with a balloon-expandable bovine pericardial valve is a less invasive option for these high-risk patients. [5, 32, 33] In a study comparing TAVR (via a transfemoral or a transapical approach) and surgical replacement in patients who were candidates for valve replacement but considered to be high risk, survival at 1 year was similar for both procedures. [34] However, important differences in periprocedural risks were observed; major vascular complications and stroke were more frequent with TAVR, whereas major bleeding and new-onset atrial fibrillation were more frequent with surgical valve replacement.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!